Summit Therapeutics Shares Are Trading Lower. The Company's Partner Akeso Received FDA Approval for Its PD-1 Monoclonal Antibody, Penpulimab-kcqx, in Combination With Cisplatin or Carboplatin and Gemcitabine. The FDA Also Approved Penpulimab-kcqx as a...
Pony.ai Shares Volatile Amid Strategic Tencent Partnership And Hesai Lidar Integration: What's Going On?
'Akeso Wins Chinese Approval For Cancer Drug Positioned To Rival Merck's Keytruda; Company Discloses Early Data Hinting At A Survival Benefit' - STAT News
Leap Motor wants to leverage the B01 to further scale up.
This is another car designed for young people.
GAC is rushing toward the new era of AI.
Continuous transformation.
China Shenhua Energy's Q1 revenue and profit both declined, with Coal sales falling by 15.3% year-on-year | Earnings Reports insights.
In the first quarter of 2025, China Shenhua Energy's revenue decreased by 21.1% year-on-year, and net income dropped by 18% year-on-year. The company attributes the decline in revenue to "a reduction in Coal sales volume and average sales price leading to a decrease in Coal sales revenue; a decline in electricity sales volume and average electricity sales price resulting in a decrease in electricity sales revenue."